Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

NCT03325556 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

392

Enrollment

INDUSTRY

Sponsor class

Conditions

Dementia-related Psychosis

Interventions

DRUG: Placebo
DRUG: Pimavanserin 34 mg
DRUG: Pimavanserin 20 mg

Sponsor

ACADIA Pharmaceuticals Inc.